MLECW Q4 2024 Earnings Call Summary

Moolec Science Q4 2024 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: Normalized revenues increased to $5.8 million in FY2024 from $1 million in FY2023, attributed to the consolidation of the soy product ingredient business.
Cost of Sales: Grew to $4.5 million from nearly $1 million, aligning with revenue growth.
Gross Margin: Specific gross margin figures were not disclosed.
Expenses: SG&A and R&D expenses rose to $9.3 million from $6.2 million, largely due to non-cash items and the consolidation of the soy ingredient business.
Cash Utilization: Increased to $9.3 million from $7.5 million, with $4 million related to lower accounts payable.
Cash Position: Approximately $5.4 million as of Q4 2024, bolstered by a convertible note to BIOX for HB4 soybean procurement.

2. Strategic Updates and Business Highlights

Regulatory Milestones: Achieved USDA approval for Piggy Sooy, marking a significant regulatory breakthrough, allowing for easier logistics and distribution.
Product Development: Successful establishment of a molecular biology lab in Texas, enabling in-house R&D and faster product development.
Commercialization Initiatives: Initiated field trials for Piggy Sooy and Glaso in multiple states, with plans for commercialization in FY2025.
Partnerships: Signed an R&D collaboration with Bunge to develop safflower varieties, enhancing productivity and market opportunities.
Offtake Agreement: Secured a three-year offtake agreement with a major global CPG company for Glaso, targeting the pet food market.

3. Forward Guidance and Outlook

FY2025 Expectations: Anticipated commercialization of Glaso, expected to contribute approximately 15% to total revenues in FY2025, with gradual growth projected.
Operational Focus: Plans to enhance operational efficiency, scale seed inventory, and improve upstream and downstream yields.
Regulatory Pathway: Continued emphasis on obtaining necessary approvals from regulatory agencies for product launches.

4. Bad News, Challenges, or Points of Concern

Increased Expenses: Rising SG&A and R&D expenses may pressure profitability.
Cash Utilization: Higher cash burn could raise concerns about liquidity, especially in a challenging market environment.
Market Education: The need for ongoing education about plant molecular farming to foster industry acceptance and understanding, which may slow adoption rates.
Dependence on Regulatory Approvals: Future product launches hinge on successful navigation of regulatory processes, which can be unpredictable.

5. Notable Q&A Insights

Commercialization Strategy: Management expressed confidence in selling the entire production of Glaso, with additional conversations ongoing for future offtake agreements.
Market Applications: Glaso is positioned for dietary supplements, nutritional beverages, and pet food, with a competitive edge due to higher GLA concentration compared to existing products.
Future Growth Potential: Management is optimistic about expanding Glaso’s market share and revenue contributions in the coming years, with expectations for significant growth by FY2026.
Investor Relations Focus: Emphasized the importance of investor communication and transparency to enhance market awareness and attract investment.

Overall, Moolec Science demonstrated significant progress in FY2024 with key regulatory approvals and strategic partnerships, while also facing challenges related to rising expenses and market education. The outlook for FY2025 appears positive, driven by new product commercialization and operational enhancements.

MLECW — Moolec Science S.A.